Something old, something new: the data that will reshape clinical trials

14 June 2017
mike_capone_large-1-

The dramatic availability of new data sources along with the opportunity to leverage existing data pools, is radically changing the way we think about clinical trials, writes Mike Capone, chief operating officer of Medidata, the provider of cloud-based solutions for clinical research, in an Expert View piece.

With the right preparation, historical trial data and genomic data will transform clinical trials, resulting in sponsors gaining insight earlier, making trials safer, and more closely achieving their therapeutic goals.

The key to the success of this transformation is understanding how to use this data for new insights without being overwhelmed by streams of new data.

Transformational change in the industry will come from both old data sources and new.

Lost opportunities and decisions made in the dark

Let’s start with the old. Thousands of clinical trials have been conducted over the years. Many of these trials result in published reports in peer-reviewed journals. This is an important resource. As sponsors develop new products, especially in the early stages, they consult published data in their therapeutic area to draw insight for their own development program. Yet we are missing a huge opportunity because data is not typically published on unsuccessful clinical trials, which means we do not learn from what has not worked in the past.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical